全文获取类型
收费全文 | 23355篇 |
免费 | 1529篇 |
国内免费 | 936篇 |
专业分类
耳鼻咽喉 | 114篇 |
儿科学 | 266篇 |
妇产科学 | 317篇 |
基础医学 | 5054篇 |
口腔科学 | 300篇 |
临床医学 | 2255篇 |
内科学 | 4106篇 |
皮肤病学 | 429篇 |
神经病学 | 525篇 |
特种医学 | 399篇 |
外国民族医学 | 9篇 |
外科学 | 2575篇 |
综合类 | 3626篇 |
现状与发展 | 8篇 |
预防医学 | 1257篇 |
眼科学 | 177篇 |
药学 | 1252篇 |
3篇 | |
中国医学 | 231篇 |
肿瘤学 | 2917篇 |
出版年
2024年 | 19篇 |
2023年 | 292篇 |
2022年 | 406篇 |
2021年 | 747篇 |
2020年 | 598篇 |
2019年 | 622篇 |
2018年 | 624篇 |
2017年 | 597篇 |
2016年 | 602篇 |
2015年 | 685篇 |
2014年 | 1104篇 |
2013年 | 1163篇 |
2012年 | 1004篇 |
2011年 | 1280篇 |
2010年 | 1038篇 |
2009年 | 1048篇 |
2008年 | 1122篇 |
2007年 | 1253篇 |
2006年 | 1118篇 |
2005年 | 1089篇 |
2004年 | 929篇 |
2003年 | 809篇 |
2002年 | 852篇 |
2001年 | 756篇 |
2000年 | 654篇 |
1999年 | 584篇 |
1998年 | 551篇 |
1997年 | 525篇 |
1996年 | 444篇 |
1995年 | 344篇 |
1994年 | 399篇 |
1993年 | 340篇 |
1992年 | 269篇 |
1991年 | 233篇 |
1990年 | 268篇 |
1989年 | 179篇 |
1988年 | 170篇 |
1987年 | 127篇 |
1986年 | 109篇 |
1985年 | 203篇 |
1984年 | 146篇 |
1983年 | 99篇 |
1982年 | 90篇 |
1981年 | 84篇 |
1980年 | 63篇 |
1979年 | 59篇 |
1978年 | 39篇 |
1977年 | 25篇 |
1976年 | 26篇 |
1973年 | 8篇 |
排序方式: 共有10000条查询结果,搜索用时 488 毫秒
21.
22.
目的 评价总前列腺特异性抗原 (tPSA)、游离前列腺特异性抗原 (fPSA)及百分率 (f/tPSA % )检测前列腺癌 (PCa)的相关性及临床价值。方法 用酶免法测定 35例PCa及 73例良性前列腺增生 (BPH)患者血清tPSA水平 ,4tPSA <10ng/ml患者另测其fPSA ,计算f/tPSA(% )。 结果 血清tPSA <4、4~ 10、>10ng/ml者发现PCa的比例组间相比均有统计学意义。 4~ 10ng/ml组 ,PCa和BPH者f/tPSA(% )分别是 9.1± 4.8、16 .4± 6 .1,差别有显著意义 (P <0 .0 1)。结论 tPSA仍是PCa筛查的有效瘤标 ,tPSA低水平时 ,f/tPSA(% )检测PCa则更为灵敏精确。 相似文献
23.
Five years experience of transrectal high-intensity focused ultrasound using the Sonablate device in the treatment of localized prostate cancer 总被引:3,自引:0,他引:3
TOYOAKI UCHIDA HIROSHI OHKUSA HIDEYUKI YAMASHITA SUNAO SHOJI YOSHIHIRO NAGATA TORU HYODO TAKEFUMI SATOH 《International journal of urology》2006,13(3):228-233
BACKGROUND: High-intensity focused ultrasound (HIFU) is a minimally invasive technique used in achieve coagulation necrosis. We evaluated biochemical disease-free survival rates, predictors of clinical outcome and morbidity in patients with localized prostate cancer treated with HIFU. METHODS: A total of 181 consecutive patients underwent HIFU with the use of Sonablate (Focus Surgery, Indianapolis, IN, USA). Biochemical recurrence was defined according to the criteria recommended by the American Society for Therapeutic Radiology and Oncology Consensus Panel. The median age and pretreatment prostate-specific antigen (PSA) level were 70 years (range 44-88) and 9.76 ng/mL (range 3.39-89.60). A total of 95 patients (52%) were treated with neoadjuvant hormones. The median follow-up period for all patients was 18.0 months (range 4-68). RESULTS: The biochemical disease-free survival rates at 1, 3 and 5 years in all patients were 84%, 80% and 78%, respectively. The biochemical disease-free survival rates at 3 years for patients with pretreatment PSA less than 10 ng/mL, 10.01-20.0 ng/mL and more than 20.0 ng/mL were 94%, 75% and 35%, respectively (P<0.0001). Multivariate analysis identified pretreatment PSA (P<0.0001) as a independent predictor of relapse. CONCLUSION: High-intensity focused ultrasound therapy appears to be a safe and efficacious minimally invasive therapy for patients with localized prostate cancer, especially those with a pretreatment PSA level less than 20 ng/mL. 相似文献
24.
The aim was to determine whether the immunogenicity of an investigational hepatitis B vaccine (spHB) is at least as high as that of a licensed control vaccine, Engerix B®, and to evaluate its safety before inclusion in new pediatric combination vaccines. Two randomized, controlled, blind-observer, Phase 3 trials were performed: one in Argentina (344 participants aged 10–15 years, 10 μg HBsAg/dose) and one in Uruguay (344 participants aged 16–45 years, 20 μg HBsAg/dose). Both vaccines were given in a 0, 1, 6 month schedule to all participants with a baseline anti-Hep B antibody titer <0.6 mIU/mL. Antibody titers were measured pre-dose 1, 1 month after dose 2, pre-dose 3, and 1 month after dose 3. Statistical non-inferiority analyses were performed on seroprotection rates (SP) post-dose 3 (% with anti-Hep B titers ≥10 mIU/mL; delta non-inferiority limit of −10%). In both studies, SP for the spHB vaccine was 100% and the spHB vaccine was non-inferior in terms of SP to the licensed control vaccine. GMTs post-dose 3 were approximately 1.8- and 4.1-fold higher for spHB in the 10–15 year and 16–45 year age groups, respectively. Reactogenicity was low for each vaccine, after each dose. This highly immunogenic hepatitis B candidate vaccine was selected for further investigation as a component of new pediatric combination vaccines. 相似文献
25.
Bacterial ghosts (BGs) are empty bacterial envelopes of Gram-negative bacteria produced by controlled expression of cloned gene E, forming a lysis tunnel structure within the envelope of the living bacteria. BGs are devoid of cytoplasmic content and possess all bacterial bio-adhesive surface properties in their original state while not posing any infectious threat. BGs are ideally suited as an advanced drug delivery system (ADDS) for toxic substances in tumor therapy. The inner space of BGs can be loaded with either single components or combinations of peptides, drugs or DNA which provides an opportunity to design new types of (polyvalent) drug delivery vehicles. Uptake of BGs loaded with Doxorubicin (Dox) by CaCo2 cells led to effective Dox release from endo-lysosomal compartments and accumulation in the nucleus. Viability and proliferative capacity of the cells were significantly decreased (2–3 orders of magnitude) after internalization of Dox loaded BGs as compared to cells incubated with free Dox. The same effect was observed with leukemia cells. Melanoma cells also revealed a high capability to internalize BGs. These results indicate that BGs are able to target a range of types of cancer. BGs have also been investigated as DNA delivery vectors. Studies show DNA loaded BGs are efficiently phagocytosed and internalized by both professional APCs and tumor cells with up to 82% of cells expressing the plasmid-encoded reporter gene. Our studies with BGs as an ADDS system contribute (i) to optimize drug delivery for the treatment of cancer; (ii) define specific conditions for selection and preparation of BG formulations; (iii) and provide a background for the clinical application of BGs in cancer therapy. 相似文献
26.
p53,p16,PCNA蛋白在食管癌中的表达及其临床意义 总被引:3,自引:0,他引:3
目的探讨p53,p16,PCNA蛋白在食管癌中的表达及临床意义。方法用免疫组织化学染色SP法对62例食管癌标本进行p53,p16,PCNA蛋白测定。结果62例食管癌中,p53,PCNA蛋白阳性表达均为71.0%(44/62),p16缺失率48.4%(30/62)。p16缺失与肿瘤浸润深度、淋巴结转移密切相关(P<0.05、P<0.01)。而p53,PCNA蛋白同时表达56.5%(35/62),亦与肿瘤浸润深度、淋巴结转移密切相关(P<0.05、P<0.01)。结论食管癌p53,PCNA蛋白同时表达及p16缺失可视为危险预后因素。 相似文献
27.
H. S. Pollinger M. D. Stegall J. M. Gloor S. B. Moore S. R. Degoey N. A. Ploeger W. D. Park H. S. Pollinger M. D. Stegall J. M. Gloor S. B. Moore S. R. Degoey N. A. Ploeger W. D. Park 《American journal of transplantation》2007,7(4):857-863
The immunologic risk associated with donor-specific antibodies (DSA) against Class II human leukocyte antigens (HLA) in kidney transplant (KTx) recipients is unclear. The aim of this study was to determine the outcome of KTx when DSA was detected only against HLA Class II. To isolate the impact of anti-Class II DSA, we retrospectively analyzed 12 KTx recipients who at baseline had a positive B-cell flow cytometric crossmatch (FXM) and a negative T-cell FXM. Using alloantibody specification analysis, 58.3% (7/12) had DSA against donor Class II and 41.7% had no demonstrable DSA. Biopsy-proven AMR occurred in 57% (4/7) in the Class II(+) group and 0% in the Class II(-) group (p > 0.05). Peritubular capillaries stained positive for C4d in 86% (6/7) of the Class II(+) patients and in 40% (2/5) of the Class II(-) patients (p > 0.05). One patient in the Class II(+) group lost their graft at 3 months to accelerated transplant glomerulopathy, while all other grafts were functioning 3-37 months posttransplant despite the persistence of anti-Class II DSA. We conclude that KTx recipients with clearly defined anti-Class II DSA are at risk for humoral rejection suggesting that desensitization and/or close posttransplant monitoring may be needed to prevent AMR. 相似文献
28.
Studies have demonstrated that lipid rafts ultimately regulate the endocytosis of anthrax toxin via clathrin dependent pathway. Interestingly, GPI-anchored protein rich rafts have also been shown to be transported down to the endocytic pathway to reducing late endosomes. Taking advantage of this parallelism, we tried translating the anthrax toxin natural intoxication mechanism by administering a DNA chimera that encoded protective antigen attached to a mammalian GPI-anchor sequence at its C-terminus (pGPI-PA63). We also designed a chimera that had an additional N-terminal TPA leader sequence (pTPA.GPI-PA63) with an aim to target GPI-PA63 to ER where new CD1 molecules are synthesized. Analysis of antibody titers demonstrated successful priming and potential IgG titers after the first boost. In vitro cell proliferation studies in the presence of GPI-attached PA63 peptides revealed that there was a clonal expansion of CD4+ NK1.1+ helper T cell population which rapidly produced IL-4 in response to T cell receptor ligation. These cells provided direct B cell help that aided IgG formation. Effector responses generated by NKT cells were found to be MHC II-independent and CD1d-restricted. In addition, the group pTPA.GPI-PA63 also displayed low magnitude MHC-II restricted (CD1d-independent) NKT cell and CD4+ T cell helper responses in response to non-GPI attached PA63 peptides which overall resulted in the heightened responses seen for this group. Importantly, DNA vaccination mediated the generation of high avidity neutralizing antibodies that mediated protection against lethal toxin challenge. 相似文献
29.
CD14+单核细胞人类白细胞抗原DR表达率与脓毒症关系的研究 总被引:15,自引:0,他引:15
目的了解烧伤延迟复苏时CDl4^+单核细胞人类白细胞抗原DR(HLA—DR)表达率的变化,分析其与脓毒症的关系。方法选择烧伤面积大于30%TBSA的25例烧伤延迟复苏患者,于伤后1、3、7、14、28d取外周血,其中7例患者住院期间并发脓毒症,于脓毒症发生后连续2d亦取其外周血。另取20例健康体检者外周血作为对照。流式细胞仪检测CD14^+单核细胞HLA.DR表达率,酶联免疫吸附测定法检测血浆中肿瘤坏死因子α(TNF—α)、白细胞介素10(IL-10)的浓度。结果非脓毒症患者伤后1、3、7、14、28dCD14^+单核细胞HLA—DR表达率分别为(15±6)%、(74±5)%、(264±17)%、(284-16)%、(474-16)%,明显低于健康体检者[(924±10)%,P〈0.01];脓毒症患者发生脓毒症后1、2d,该指标亦明显低于健康体检者及非脓毒症患者伤后1、7、14、28d(P〈0.01)。脓毒症患者TNF—d检出率及TNF—α、IL-10浓度,均高于非脓毒症患者和健康体检者(P〈0.05或P〈0.01)。伤后1、7、28d,外周血CD14^+单核细胞HLA—DR表达率与IL—10浓度呈显著负相关(r分别为-0.9963、-0.7459、-0.8474,P〈0.01)。结论烧伤延迟复苏患者免疫功能低下,促炎性介质释放量增加,并发脓毒症时则更为严重。外周血CD14^+单核细胞HLA—DR表达率可作为动态检测患者免疫功能状态的有效指标。 相似文献
30.
Permanent prostate brachytherapy for Japanese men: Results from initial 100 patients with prostate cancer 总被引:1,自引:1,他引:0
Toshikazu Okaneya Shuji Nishizawa Tsuyoshi Nakayama Takayuki Kamigaito Iwao Hashida Noriko Hosaka 《International journal of urology》2007,14(7):602-606
OBJECTIVE: To evaluate the initial results of brachytherapy for prostate cancer with permanent iodine-125 implant in Japan. METHODS: The results obtained with brachytherapy in the initial 100 Japanese patients treated at Nagano Municipal Hospital were reviewed. Patients with a prostate-specific antigen (PSA) level of less than 10 ng/mL and a Gleason's scores of 5, 6, 3 + 4 were classified as having a low risk of recurrence. Patients with a PSA level of 10-20 ng/mL and/or a Gleason's score of 4 + 3 were classified as having an intermediate risk for recurrence. Seventy-eight of the low-risk patients and 19 of the intermediate-risk patients were treated by seed implants alone, or seed implants combined with preceding external radiation, respectively. A total of 53 patients received neoadjuvant hormone therapy. The efficacy and morbidity of brachytherapy were investigated using the serum PSA, International Prostate Symptom Score, quality of life score and uroflowmetry data. RESULTS: The average V100 and D90 obtained by post-implant dosimetry was 94.3 and 113.7%, respectively. Serum PSA decreased gradually after treatment, although it had still not reached a nadir after 1 year. There was little difference of the PSA level between the patients with and without neoadjuvant hormone therapy even at 1 year after seed implantation. There were no PSA biochemical failure or clinical recurrence during the follow-up period. Voiding symptoms worsened until 3 months after treatment, and then gradually improved. Acute urinary retention occurred transiently in one patient (1%). Rectal bleeding and severe diarrhea did not occur. CONCLUSION: Brachytherapy is a feasible and effective option for the treatment of prostate cancer in Japanese men. Brachytherapy may have a different effect in Japanese patients with respect to voiding symptoms. Urinary retention was rare, but voiding symptoms were persistent in Japanese patients. Neoadjuvant hormone therapy deserves investigation to determine whether it can achieve better results, especially in patients with an intermediate risk. 相似文献